Considering all somatic variants determined by whole genome or whole exome sequencing in 85 available tumor samples, activating CTNNB1 variants (13/85, 15.3%) were the most common, followed by DROSHA (7/85, 8.2%), BCORL1/BCOR (5/85, 5.9%), DGCR8 (4/85, 4.7%), TP53 (4/85, 4.7%), SIX1/2 (4/85, 4.7%), C22orf34 (3/85, 3.5%), MAP3K4 (3/85, 3.5%), MYCN (3/85, 3.5%), and RERE (3/85, 3.5%). Here, RERE is linked to neoplasm.